β-defensin 50 Inhibitors
β-defensin 50 inhibitors represent a class of compounds designed to specifically interact with β-defensin 50, a member of the defensin family of small antimicrobial peptides. Defensins are known for their role in the innate immune system, where they contribute to host defense by disrupting the integrity of microbial membranes. β-defensin 50 is unique among defensins in its structure, composition, and the specific pathways it modulates within various biological processes. The inhibition of β-defensin 50 is thought to modulate its activity, which involves intricate interactions with cellular membranes and potentially affects signal transduction pathways, cellular proliferation, and other molecular mechanisms associated with cellular homeostasis and immune responses. Compounds that inhibit β-defensin 50 are typically studied for their ability to bind to specific regions of the peptide, altering its structural conformation and thereby its interaction with other biomolecules or cellular components.
The development of β-defensin 50 inhibitors requires a comprehensive understanding of the peptide's structure-function relationship. This involves high-resolution structural studies such as X-ray crystallography and NMR spectroscopy to elucidate the active sites and the conformational changes induced upon binding with potential inhibitors. Additionally, computational modeling and molecular dynamics simulations play a crucial role in predicting how these inhibitors interact with β-defensin 50 at the atomic level. Research into β-defensin 50 inhibitors also involves studying the compound's specificity, stability, and interaction kinetics to ensure that they effectively target β-defensin 50 without off-target effects on other defensin family members or unrelated proteins. Understanding these intricate biochemical interactions and structural requirements is essential for advancing the basic scientific knowledge of β-defensin 50 and its role in cellular processes, providing a foundation for further exploration in various fields of molecular biology and biochemistry.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFR kinase inhibitor disrupting the MAPK/ERK pathway. Erlotinib indirectly inhibits β-defensin 50 by interfering with the EGFR/MAPK/ERK pathway, known to modulate β-defensin 50 transcription through specific transcription factors. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI3K/mTOR dual inhibitor affecting the PI3K/AKT/mTOR pathway. PI-103 indirectly suppresses β-defensin 50, as the PI3K/AKT/mTOR pathway regulates β-defensin 50 transcription through specific transcription factors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly suppresses β-defensin 50, as PI3K/AKT signaling regulates β-defensin 50 transcription through specific transcription factors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor disrupting mTOR signaling. Rapamycin indirectly influences β-defensin 50 expression by interfering with the mTOR pathway, known to modulate β-defensin 50 transcription through specific transcription factors. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPK inhibitor affecting the MAPK pathway. SB203580 indirectly inhibits β-defensin 50 by disrupting the p38 MAPK pathway, known to modulate β-defensin 50 transcription through specific transcription factors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 50, as PI3K/AKT signaling regulates β-defensin 50 transcription through specific transcription factors. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor impacting NF-κB signaling. Bortezomib indirectly hampers β-defensin 50 expression by blocking the proteasome, affecting the degradation of IκB and subsequent NF-κB activation, a pathway known to modulate β-defensin 50 transcription through specific transcription factors. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $148.00 $452.00 | 1 | |
H3K27 methyltransferase inhibitor. GSK343 indirectly influences β-defensin 50 by altering histone methylation, impacting the chromatin structure and accessibility of the β-defensin 50 gene for transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor modulating chromatin structure. Trichostatin A indirectly suppresses β-defensin 50 by altering histone acetylation, influencing the accessibility of the β-defensin 50 gene for transcription. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
DNA-damaging agent affecting multiple pathways. Cisplatin indirectly influences β-defensin 50 by causing DNA damage, triggering various stress response pathways that modulate β-defensin 50 transcription through specific transcription factors. | ||||||